Skip to main content

Zentalis Pharmaceuticals, Inc.

ZNTL
Exchange
Nasdaq
Industry
Pharmaceutical Preparations
SEC CIK
0001725160

In the last 90 days, Zentalis Pharmaceuticals, Inc. insiders filed 1 open-market purchase and 0 sales; 114 institutions reported holding it in 13F filings for Q2 2026, worth $228.9M in total; no superinvestor holds it.

13F holders, Q1 2024

Institutional positions in Zentalis Pharmaceuticals, Inc. as of Mar 31, 2024. Investment managers with $100 million or more in US stocks report their long positions on Form 13F within 45 days after each quarter ends. How 13F works

Institutional holders
142
+22 vs. Q4 2023
Shares held
85.3M
+4.22M (+5.2%) vs. Q4 2023
Total value
$1.34B
+$116.0M (+9.4%) vs. Q4 2023
New holders
36
44 more added
Sold out
14
37 more reduced

Compare with Q4 2023: new holders, sold out and not filed yet

Holders and value by quarter

Institutions reporting ZNTL on Form 13F each quarter since Q1 2021, and the total value they reported. Values are as of each quarter end, so they also move with the share price.

Institutional holdersQ1 2024: 142 institutions
Q1 2021: 95 institutionsQ2 2021: 120 institutionsQ3 2021: 116 institutionsQ4 2021: 139 institutionsQ1 2022: 128 institutionsQ2 2022: 122 institutionsQ3 2022: 121 institutionsQ4 2022: 106 institutionsQ1 2023: 110 institutionsQ2 2023: 134 institutionsQ3 2023: 137 institutionsQ4 2023: 120 institutionsQ1 2024: 142 institutionsQ2 2024: 145 institutionsQ3 2024: 136 institutionsQ4 2024: 142 institutionsQ1 2025: 132 institutionsQ2 2025: 117 institutionsQ3 2025: 99 institutionsQ4 2025: 86 institutionsQ1 2026: 102 institutionsQ2 2026: 114 institutions
Value heldQ1 2024: $1.34B
Q1 2021: $1.58BQ2 2021: $2.13BQ3 2021: $2.75BQ4 2021: $3.61BQ1 2022: $2.05BQ2 2022: $1.64BQ3 2022: $1.27BQ4 2022: $1.30BQ1 2023: $1.15BQ2 2023: $2.32BQ3 2023: $1.61BQ4 2023: $1.23BQ1 2024: $1.34BQ2 2024: $314.3MQ3 2024: $261.2MQ4 2024: $195.2MQ1 2025: $92.9MQ2 2025: $64.5MQ3 2025: $79.7MQ4 2025: $54.9MQ1 2026: $101.7MQ2 2026: $228.9M
Institutions holding ZNTL and their total value by quarter
QuarterHoldersValue
Q2 2026114$228.9M
Q1 2026102$101.7M
Q4 202586$54.9M
Q3 202599$79.7M
Q2 2025117$64.5M
Q1 2025132$92.9M
Q4 2024142$195.2M
Q3 2024136$261.2M
Q2 2024145$314.3M
Q1 2024142$1.34B
Q4 2023120$1.23B
Q3 2023137$1.61B
Q2 2023134$2.32B
Q1 2023110$1.15B
Q4 2022106$1.30B
Q3 2022121$1.27B
Q2 2022122$1.64B
Q1 2022128$2.05B
Q4 2021139$3.61B
Q3 2021116$2.75B
Q2 2021120$2.13B
Q1 202195$1.58B

Institutions, Q1 2024

Shares, value and share of portfolio for each institution holding Zentalis Pharmaceuticals, Inc.; share changes are against Q4 2023.

Institutions holding ZNTL in Q1 2024
InstitutionSharesValue% of portfolioChange in sharesAction
Nuveen Asset Management, LLC130,308$2.05M0.00%00.0%Unchanged
PDT Partners, LLC131,263$2.07M0.20%+131,263New
Manufacturers Life Insurance Company, The131,815$2.08M0.00%+14,921+12.8%Added
Norges Bank142,956$2.25M0.00%−21,386−13.0%Reduced
Voya Investment Management LLC144,623$2.28M0.00%−4,232−2.8%Reduced
Mayo Clinic187,143$2.95M48.00%00.0%Unchanged
Opaleye Management Inc.200,000$3.15M0.69%+200,000New
Two Sigma Investments, LP244,995$3.86M0.01%+244,995New
Millennium Management LLC246,322$3.88M0.00%+215,627+702.5%Added
Citigroup Inc257,087$4.05M0.00%+111,169+76.2%Added
TD Asset Management Inc258,818$4.08M0.00%+68,650+36.1%Added
Renaissance Technologies LLC261,937$4.13M0.01%−47,340−15.3%Reduced
UBS Group AG267,865$4.22M0.00%+267,755+243,413.6%Added
Bank of New York Mellon Corp289,880$4.57M0.00%−256−0.1%Reduced
Rafferty Asset Management, LLC298,008$4.70M0.02%−62,117−17.2%Reduced
Goldman Sachs Group Inc332,000$5.23M0.00%+39,119+13.4%Added
Boxer Capital, LLC450,000$7.09M0.35%00.0%Unchanged
Charles Schwab Investment Management Inc455,937$7.19M0.00%+10,114+2.3%Added
Bank of America Corp475,956$7.50M0.00%−242,687−33.8%Reduced
5AM Venture Management, LLC490,000$7.72M1.73%00.0%Unchanged
Northern Trust Corp523,702$8.25M0.00%−6,301−1.2%Reduced
Dimensional Fund Advisors LP723,656$11.4M0.00%−377−0.1%Reduced
Paradigm Biocapital Advisors LP944,917$14.9M0.52%+544,917+136.2%Added
Tybourne Capital Management (HK) Ltd961,486$15.2M2.59%00.0%Unchanged
Morgan Stanley1,037,409$16.3M0.00%+427,926+70.2%Added
Verition Fund Management LLC1,155,236$18.2M0.17%+810,619+235.2%Added
Primecap Management Co1,164,610$18.4M0.01%+141,260+13.8%Added
Geode Capital Management, LLC1,302,237$20.5M0.00%+48,500+3.9%Added
Woodline Partners LP1,437,026$22.6M0.21%+33,473+2.4%Added
MPM Oncology Impact Management LP1,516,183$23.9M3.84%+1,516,183New
Federated Hermes, Inc.1,998,700$31.5M0.07%−161,865−7.5%Reduced
Decheng Capital LLC2,099,583$33.1M4.44%00.0%Unchanged
Capital International Investors2,819,664$44.4M0.01%00.0%Unchanged
T. Rowe Price Investment Management, Inc.3,319,086$52.3M0.03%+977,303+41.7%Added
Price T Rowe Associates Inc3,489,709$55.0M0.01%+585,644+20.2%Added
State Street Corp3,785,652$59.7M0.00%−631,404−14.3%Reduced
Citadel Advisors LLC3,852,429$60.7M0.06%+170,647+4.6%Added
Vanguard Group Inc4,398,625$69.3M0.00%−951,833−17.8%Reduced
BlackRock Inc.4,645,758$73.2M0.00%−39,217−0.8%Reduced
FMR LLC10,644,024$167.7M0.01%+307,053+3.0%Added
Eventide Asset Management, LLC11,574,821$182.4M2.86%+14,846+0.1%Added
Matrix Capital Management Company, LP13,959,973$220.0M2.04%00.0%Unchanged
Integral Health Asset Management, LLC0$00.00%−250,000−100.0%Sold out
Ensign Peak Advisors, Inc0$00.00%−194,933−100.0%Sold out
Voloridge Investment Management, LLC0$00.00%−175,537−100.0%Sold out
SG Americas Securities, LLC0$00.00%−152,747−100.0%Sold out
Caption Management, LLC0$00.00%−125,727−100.0%Sold out
Wellington Management Group LLP0$00.00%−68,791−100.0%Sold out
Qube Research & Technologies Ltd0$00.00%−50,202−100.0%Sold out
Standard Life Aberdeen plc0$00.00%−40,156−100.0%Sold out
Algert Global LLC0$00.00%−33,350−100.0%Sold out
Simplex Trading, LLC0$00.00%−31,078−100.0%Sold out
HighTower Advisors, LLC0$00.00%−29,905−100.0%Sold out
Group One Trading, L.P.0$00.00%−28,608−100.0%Sold out
Sectoral Asset Management Inc0$00.00%−7,355−100.0%Sold out
Arlington Trust Co LLC0$00.00%−70−100.0%Sold out